Canada Home

Paving the way for access to innovative specialty, rare disease, and biosimilar medicines for Canadian patients

Learn More

Welcome to ADVANZ PHARMA Canada

ADVANZ PHARMA Canada Inc. is a full-scale pharmaceutical company specializing in the commercialization of innovative specialty, rare disease, and biosimilar products, that serve the unique needs of patients and health systems.

Our organization possesses the commercial, market access, regulatory, and medical affairs capabilities that are necessary to deliver patient-centric solutions that add value to patients and health systems across Canada.

We are committed to addressing the unmet needs of patients by placing them at the center of everything we do. Our patient-centric approach ensures that our products and services are tailored to meet the unique needs of each patient population we serve, and we are constantly exploring new ways to improve the lives of patient care.

Our portfolio —

ADVANZ PHARMA Canada’s product portfolio and pipeline comprises innovative medicines, complex generics & biosimilars, and originator brands. Our products cover a broad range of therapeutic areas, including hepatology, gastroenterology, oncology, and, more broadly, rare diseases.

Careers & Culture —

The success of any company is driven by it’s people. We are no different. We believe in creating a collaborative, supportive, and flexible working environment. Our highly experienced team is encouraged to be creative, come together, and embrace change. As an organization, we are committed to investing in the growth of our people.

Latest News —

Image for ADVANZ PHARMA and Enzene Enter an Exclusive Partnership for Biosimilar Development and Commercialisation

Press Releases — 27 Aug. 2024

ADVANZ PHARMA and Enzene Enter an Exclusive Partnership for Biosimilar Development and Commercialisation

Learn more
Image for European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Press Releases — 15 Aug. 2024

European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Learn more
Image for Alvotech and ADVANZ PHARMA Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe

Press Releases — 18 Jun. 2024

Alvotech and ADVANZ PHARMA Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe

Learn more
Image for ADVANZ PHARMA and Allecra Therapeutics announce approval in the European Union for the new antibiotic combination EXBLIFEP® (cefepime/enmetazobactam) for the treatment of severe infections

Press Releases — 27 Mar. 2024

ADVANZ PHARMA and Allecra Therapeutics announce approval in the European Union for the new antibiotic combination EXBLIFEP® (cefepime/enmetazobactam) for the treatment of severe infections

Learn more
Image for ADVANZ PHARMA receives positive CHMP opinion for EXBLIFEP® (cefepime/enmetazobactam)

Press Releases — 26 Jan. 2024

ADVANZ PHARMA receives positive CHMP opinion for EXBLIFEP® (cefepime/enmetazobactam)

Learn more
Image for ADVANZ PHARMA acquires global rights to Androcur® from Bayer

Press Releases — 07 Nov. 2023

ADVANZ PHARMA acquires global rights to Androcur® from Bayer

Learn more